Novartis' Ilaris Gets Thumbs Down as Gout Treatment
By Mari Serebrov
Wednesday, June 22, 2011
Novartis AG may have proven the efficacy of its Ilaris to treat gouty arthritis attacks, but it couldn't overcome the safety concerns.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.